Published in Immunology on March 27, 2008
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One (2010) 1.61
Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. Am J Pathol (2010) 1.57
Specific-sized hyaluronan fragments promote expression of human β-defensin 2 in intestinal epithelium. J Biol Chem (2012) 1.05
ZBP-89 regulates expression of tryptophan hydroxylase I and mucosal defense against Salmonella typhimurium in mice. Gastroenterology (2013) 1.00
Butyrate enhances disease resistance of chickens by inducing antimicrobial host defense peptide gene expression. PLoS One (2011) 0.99
Identification of NF-κB modulation capabilities within human intestinal commensal bacteria. J Biomed Biotechnol (2011) 0.94
Dietary, metabolic, and potentially environmental modulation of the lysine acetylation machinery. Int J Cell Biol (2010) 0.90
Modulation of antimicrobial host defense peptide gene expression by free fatty acids. PLoS One (2012) 0.87
Induction of porcine host defense peptide gene expression by short-chain fatty acids and their analogs. PLoS One (2013) 0.85
Dietary epigenetics in cancer and aging. Cancer Treat Res (2014) 0.85
Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges. Semin Cancer Biol (2016) 0.83
Colonic MUC2 mucin regulates the expression and antimicrobial activity of β-defensin 2. Mucosal Immunol (2015) 0.81
Regulation of antimicrobial peptide gene expression by nutrients and by-products of microbial metabolism. Eur J Nutr (2012) 0.81
Sulforaphane and Other Nutrigenomic Nrf2 Activators: Can the Clinician's Expectation Be Matched by the Reality? Oxid Med Cell Longev (2016) 0.80
Antimicrobial Human β-Defensins in the Colon and Their Role in Infectious and Non-Infectious Diseases. Pathogens (2013) 0.80
The Effect of Lactobacillus casei 32G on the Mouse Cecum Microbiota and Innate Immune Response Is Dose and Time Dependent. PLoS One (2015) 0.78
Sulforaphane inhibits TNF-α-induced adhesion molecule expression through the Rho A/ROCK/NF-κB signaling pathway. J Med Food (2014) 0.76
Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections. Antibiotics (Basel) (2015) 0.76
1,25-Dihydroxyvitamin-D3 Induces Avian β-Defensin Gene Expression in Chickens. PLoS One (2016) 0.75
Sulforaphane epigenetically regulates innate immune responses of porcine monocyte-derived dendritic cells induced with lipopolysaccharide. PLoS One (2015) 0.75
Sodium butyrate improves porcine host defense peptide expression and relieves the inflammatory response upon Toll-like receptor 2 activation and histone deacetylase inhibition in porcine kidney cells. Oncotarget (2017) 0.75
Mammalian MAP kinase signalling cascades. Nature (2001) 18.89
Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 11.11
The MAPK signaling cascade. FASEB J (1995) 10.81
Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev (1999) 9.94
Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol (2004) 6.35
Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 5.99
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
War and peace at mucosal surfaces. Nat Rev Immunol (2004) 4.00
Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 3.39
Noncalcemic actions of vitamin D receptor ligands. Endocr Rev (2005) 3.34
p38 MAP kinases: beyond the stress response. Trends Biochem Sci (2000) 3.20
Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr (2004) 3.11
A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res (2004) 2.71
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun (2004) 2.47
Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J Invest Dermatol (2007) 2.45
Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ (2001) 2.27
Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem (2001) 2.26
Host defense peptides as new weapons in cancer treatment. Cell Mol Life Sci (2005) 2.08
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem (2007) 2.07
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J (2006) 1.98
Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. Gut (2003) 1.97
Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology (2006) 1.88
A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem (2000) 1.87
Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. Infect Immun (2002) 1.80
Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett (2005) 1.78
Antimicrobial peptides in health and disease. N Engl J Med (2002) 1.78
p38 pathway kinases as anti-inflammatory drug targets. J Dent Res (2007) 1.71
Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Am J Physiol Endocrinol Metab (2006) 1.68
Human beta-defensin 2 but not beta-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease. Eur J Gastroenterol Hepatol (2002) 1.59
Modulatory properties of various natural chemopreventive agents on the activation of NF-kappaB signaling pathway. Pharm Res (2004) 1.53
Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut (2000) 1.52
Induction of human beta-defensin 2 by the probiotic Escherichia coli Nissle 1917 is mediated through flagellin. Infect Immun (2007) 1.48
Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? Carcinogenesis (2005) 1.46
Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis (2004) 1.42
Defensins and innate host defence of the gastrointestinal tract. Gut (1999) 1.41
Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr (2000) 1.40
Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets (2006) 1.40
Inhibition of angiogenesis and endothelial cell functions are novel sulforaphane-mediated mechanisms in chemoprevention. Mol Cancer Ther (2006) 1.38
Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. Mol Immunol (2004) 1.32
Mechanisms of disease: defensins in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol (2005) 1.27
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol (2005) 1.27
Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol (2004) 1.26
p53-independent G1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol (2005) 1.24
Role of PI3K/Akt and MEK/ERK signaling pathways in sulforaphane- and erucin-induced phase II enzymes and MRP2 transcription, G2/M arrest and cell death in Caco-2 cells. Biochem Pharmacol (2005) 1.20
Active ERK contributes to protein translation by preventing JNK-dependent inhibition of protein phosphatase 1. J Immunol (2006) 1.19
Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action. J Immunol (1999) 1.19
Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol (2007) 1.12
Sulforaphane as a promising molecule for fighting cancer. Mutat Res (2006) 1.12
Mapping of the gene encoding human beta-defensin-2 (DEFB2) to chromosome region 8p22-p23.1. Genomics (1997) 1.05
Transcriptome analysis of human colon Caco-2 cells exposed to sulforaphane. J Nutr (2005) 1.03
Activation of a Src-dependent Raf-MEK1/2-ERK signaling pathway is required for IL-1alpha-induced upregulation of beta-defensin 2 in human middle ear epithelial cells. Biochim Biophys Acta (2002) 1.02
The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med (2003) 1.02
Defence molecules in intestinal innate immunity against bacterial infections. Curr Opin Gastroenterol (2005) 1.00
Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res (2004) 0.99
Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol Immunol (2006) 0.98
Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol (2007) 0.98
Defending the epithelium. Nat Med (2006) 0.95
Dietary agents as histone deacetylase inhibitors. Mol Carcinog (2006) 0.95
Up-regulation of human beta-defensin 2 by interleukin-1beta in A549 cells: involvement of PI3K, PKC, p38 MAPK, JNK, and NF-kappaB. Biochem Biophys Res Commun (2004) 0.95
Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain? Am J Physiol Gastrointest Liver Physiol (2002) 0.95
Paneth cells and the innate immune response. Curr Opin Gastroenterol (2006) 0.91
Beta-defensin production by human colonic plasma cells: a new look at plasma cells in ulcerative colitis. Inflamm Bowel Dis (2007) 0.90
Innate immunity and mucosal bacterial interactions in the intestine. Curr Opin Gastroenterol (2004) 0.87
Butyrate-induced differentiation of Caco-2 cells is mediated by vitamin D receptor. Biochem Biophys Res Commun (2001) 0.87
Immunomodulatory activity of Sulforaphane, a naturally occurring isothiocyanate from broccoli (Brassica oleracea). Phytomedicine (2006) 0.87
Human defensins in Crohn's disease. Chem Immunol Allergy (2005) 0.86
PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun (2000) 0.85
Short-chain fatty acids and colon cancer cells: the vitamin D receptor--butyrate connection. Recent Results Cancer Res (2003) 0.83
PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis (2006) 0.81
Expression of beta-defensin-2 in human gastric tumors: a pilot study. Exp Oncol (2005) 0.78
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology (2011) 2.64
5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci (2007) 2.53
Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis (2013) 2.13
Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Am J Gastroenterol (2005) 1.93
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest (2011) 1.88
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther (2006) 1.53
Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med (2008) 1.23
The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem (2001) 1.22
Mechanical stretch stimulates protein kinase B/Akt phosphorylation in epidermal cells via angiotensin II type 1 receptor and epidermal growth factor receptor. J Biol Chem (2004) 1.19
Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol (2008) 1.18
Carnosic acid and carnosol potently inhibit human 5-lipoxygenase and suppress pro-inflammatory responses of stimulated human polymorphonuclear leukocytes. Biochem Pharmacol (2008) 1.14
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol (2002) 1.13
Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci U S A (2006) 1.12
Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood (2002) 1.12
Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol (2009) 1.11
Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. FASEB J (2002) 1.07
Functional characterization of vitamin D responding regions in the human 5-Lipoxygenase gene. Biochim Biophys Acta (2007) 1.06
Prevalence of anemia in inflammatory bowel diseases in european countries: a systematic review and individual patient data meta-analysis. Inflamm Bowel Dis (2014) 1.05
Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins. Proc Natl Acad Sci U S A (2004) 1.04
Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.03
New introducer PEG gastropexy does not require prophylactic antibiotics: multicenter prospective randomized double-blind placebo-controlled study. Gastrointest Endosc (2008) 1.02
Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr (2002) 1.02
Health-related quality of life in adult coeliac disease in Germany: results of a national survey. Eur J Gastroenterol Hepatol (2006) 1.00
Development and validation of the Celiac Disease Questionnaire (CDQ), a disease-specific health-related quality of life measure for adult patients with celiac disease. J Clin Gastroenterol (2007) 1.00
The new low calcemic vitamin D analog 22-ene-25-oxa-vitamin D prominently ameliorates T helper cell type 1-mediated colitis in mice. J Pharmacol Exp Ther (2006) 1.00
Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol (2008) 0.99
Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Mol Immunol (2006) 0.98
Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol (2007) 0.98
PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis (2008) 0.97
Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochem Biophys Res Commun (2003) 0.97
Development of 5-lipoxygenase inhibitors--lessons from cellular enzyme regulation. Biochem Pharmacol (2005) 0.97
Influence of dTMP on the phenotypic appearance and intracellular persistence of Staphylococcus aureus. Infect Immun (2007) 0.97
Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin Chem (2005) 0.97
Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPK-activated protein kinase 2 (MK2). J Biol Chem (2002) 0.96
Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J (2003) 0.95
Investigation of imatinib and other approved drugs as starting points for antidiabetic drug discovery with FXR modulating activity. Biochem Pharmacol (2012) 0.94
Boswellic acids activate p42(MAPK) and p38 MAPK and stimulate Ca(2+) mobilization. Biochem Biophys Res Commun (2002) 0.93
The histone deacetylase inhibitor trichostatin A mediates upregulation of 5-lipoxygenase promoter activity by recruitment of Sp1 to distinct GC-boxes. Biochim Biophys Acta (2007) 0.92
Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. Curr Pharm Biotechnol (2012) 0.92
Differential induction of BLT receptor expression on human endothelial cells by lipopolysaccharide, cytokines, and leukotriene B4. Proc Natl Acad Sci U S A (2006) 0.92
Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci (2006) 0.92
Dimerization of human 5-lipoxygenase. Biol Chem (2011) 0.91
Inadequate nutrient intake in patients with celiac disease: results from a German dietary survey. Digestion (2013) 0.91
Dominant expression of the CysLT2 receptor accounts for calcium signaling by cysteinyl leukotrienes in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol (2003) 0.90
Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102. Biochem J (2009) 0.90
Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther (2012) 0.89
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. J Pharmacol Exp Ther (2012) 0.88
TLR2 ligands augment cPLA2alpha activity and lead to enhanced leukotriene release in human monocytes. J Leukoc Biol (2009) 0.88
Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol Pharmacol (2013) 0.87
Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J Leukoc Biol (2003) 0.87
Analysis of the 5-lipoxygenase promoter and characterization of a vitamin D receptor binding site. Biochim Biophys Acta (2006) 0.87
Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: key role of polyamines? J Nutr (2004) 0.87
De novo ceramide biosynthesis is associated with resveratrol-induced inhibition of ornithine decarboxylase activity. Biochem Pharmacol (2007) 0.86
Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis (2003) 0.86
Inhibitors of actin polymerisation stimulate arachidonic acid release and 5-lipoxygenase activation by upregulation of Ca2+ mobilisation in polymorphonuclear leukocytes involving Src family kinases. Biochim Biophys Acta (2005) 0.86
Posttranslational modification of E. coli histone-like protein H-NS and bovine histones by short-chain poly-(R)-3-hydroxybutyrate (cPHB). FEBS Lett (2002) 0.86
Trichostatin A and structurally related histone deacetylase inhibitors induce 5-lipoxygenase promoter activity. Biol Chem (2003) 0.86
Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem (2008) 0.86
The TGFbeta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. J Cell Biochem (2007) 0.86
Calcitriol upregulates open chromatin and elongation markers at functional vitamin D response elements in the distal part of the 5-lipoxygenase gene. J Mol Biol (2009) 0.85
Comparison of a novel fecal marker--fecal tumor pyruvate kinase type M2 (M2-PK) with fecal calprotectin in patients with inflammatory bowel disease: a prospective study. Clin Lab (2008) 0.85
Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. Eur J Nutr (2003) 0.85
Total body metabolism of 13C-octanoic acid is preserved in patients with non-alcoholic steatohepatitis, but differs between women and men. Eur J Gastroenterol Hepatol (2005) 0.85
Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol (2006) 0.85
Fecal tumor M2 pyruvate kinase is not a specific biomarker for colorectal cancer screening. World J Gastroenterol (2007) 0.85
Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol (2004) 0.85
Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. Basic Clin Pharmacol Toxicol (2013) 0.85
5-Lipoxygenase inhibitors: a review of recent patents (2010-2012). Expert Opin Ther Pat (2013) 0.85
The aminosteroid phospholipase C antagonist U-73122 (1-[6-[[17-beta-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione) potently inhibits human 5-lipoxygenase in vivo and in vitro. Mol Pharmacol (2005) 0.85
Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells. Proc Natl Acad Sci U S A (2005) 0.85
The coding sequence mediates induction of 5-lipoxygenase expression by Smads3/4. Biochem Biophys Res Commun (2006) 0.85
Nitric oxide mediates distinct effects of various LPS chemotypes on phagocytosis and leukotriene synthesis in human neutrophils. Int J Biochem Cell Biol (2010) 0.85
Extraction and visualization of potential pharmacophore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. J Med Chem (2005) 0.84
Expression of human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult cystic fibrosis patients, healthy individuals, and individuals with acute cold. Respiration (2002) 0.84
Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem (2007) 0.84
Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci (2009) 0.83
Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res (2006) 0.83
Short-chain fatty acids and colon cancer cells: the vitamin D receptor--butyrate connection. Recent Results Cancer Res (2003) 0.83
p38 MAPK signaling pathway is involved in butyrate-induced vitamin D receptor expression. Biochem Biophys Res Commun (2004) 0.83